3-Deazaadenosine

• UNSPSC Description:

  3-Deazaadenosine is an inhibitor of S-adenosylhomocysteine hydrolase, with a Ki of 3.9 μM; 3-Deazaadenosine has anti-inflammatory, anti-proliferative and anti-HIV activity.

• Target Antigen:

  HIV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/3-Deazaadenosine.html

• Purity:

  99.87

• Solubility:

  DMSO : 130 mg/mL (ultrasonic)|H2O : 100 mg/mL (ultrasonic)

• Smiles:

  O[C@H]1[C@@H](O[C@H](CO)[C@H]1O)N2C3=C(C(N)=NC=C3)N=C2

• Molecular Weight:

  266.257

• References & Citations:

  [1]Gordon RK, et al. Anti-HIV-1 activity of 3-deaza-adenosine analogs. Inhibition of S-adenosylhomocysteine hydrolase and nucleotide congeners. Eur J Biochem. 2003 Sep;270(17):3507-17.|[2]Jeong SY, et al. 3-deazaadenosine, a S-adenosylhomocysteine hydrolase inhibitor, has dual effects on NF-kappaB regulation. Inhibition of NF-kappaB transcriptional activity and promotion of IkappaBalpha degradation. J Biol Chem. 1999 Jul 2;274(27):18981-8.|[3]Sedding DG, et al. 3-Deazaadenosine prevents smooth muscle cell proliferation and neointima formation by interfering with Ras signaling. Circ Res. 2009 May 22;104(10):1192-200.Am J Physiol Cell Physiol. 2023 Dec 25.|Arch Toxicol. 2021 Jan;95(1):299-309.|BMC Biol. 2024 May 3;22(1):104.|Cancer Cell Int. 2023 Dec 18;23(1):330.|Cancer Res. 2021 Sep 15;81(18):4778-4793.|Cell Mol Biol Lett. 2024 Jul 3;29(1):97.|Cell Rep. 2021 Jan 5;34(1):108580.|Environ Pollut. 2023 May 9;121798.|Exp Cell Res. 2024 Aug 27:114226.|Genomics. 2022 Jul 4;110424.|Int J Biol Sci. 2023; 19(2):593-609.|J Cancer. 2023 Apr 17; 14(7): 1117-1131.|J Neurosci. 2023 Jan 17;JN-RM-1209-22.|Oncogene. 2024 Mar 5.|Research Square Print. 2022 May.|Transpl Immunol. 2024 Jul 10:102083.|bioRxiv. 2024 May 18.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  6736-58-9